RepliCel Historical Cash Flow
| RP Stock | CAD 0.01 0.00 0.00% |
Analysis of RepliCel Life cash flow over time is an excellent tool to project RepliCel Life Sciences future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Total Cash From Financing Activities of 1.8 M or End Period Cash Flow of 56.2 K as it is a great indicator of RepliCel Life ability to facilitate future growth, repay debt on time or pay out dividends.
Financial Statement Analysis is much more than just reviewing and examining RepliCel Life Sciences latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether RepliCel Life Sciences is a good buy for the upcoming year.
RepliCel |
About RepliCel Cash Flow Analysis
The Cash Flow Statement is a financial statement that shows how changes in RepliCel balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which RepliCel's non-liquid assets can be easily converted into cash.
RepliCel Life Cash Flow Chart
Add Fundamental
Begin Period Cash Flow
The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.Depreciation
Depreciation indicates how much of RepliCel Life Sciences value has been used up. For tax purposes RepliCel Life can deduct the cost of the tangible assets it purchases as business expenses. However, RepliCel Life Sciences must depreciate these assets in accordance with IRS rules about how and when the deduction may be taken, and how long it will last. The systematic allocation of the cost of a tangible asset over its useful life.Most accounts from RepliCel Life's cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into RepliCel Life Sciences current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in RepliCel Life Sciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. At this time, RepliCel Life's Begin Period Cash Flow is fairly stable compared to the past year. Other Cashflows From Financing Activities is likely to climb to about 3.3 M in 2024, whereas Free Cash Flow is likely to drop (1.5 M) in 2024.
| 2023 | 2024 (projected) | Sale Purchase Of Stock | 5.4M | 4.0M | Depreciation | 1.5K | 1.4K |
RepliCel Life cash flow statement Correlations
Click cells to compare fundamentals
RepliCel Life Account Relationship Matchups
High Positive Relationship
High Negative Relationship
RepliCel Life cash flow statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change In Cash | (2.4M) | 10.4K | 186.8K | 191.8K | (353.9K) | (336.2K) | |
| Free Cash Flow | (2.8M) | (765.2K) | (2.5M) | (1.4M) | (1.4M) | (1.5M) | |
| Change In Working Capital | 444.9K | 916.0K | (324.2K) | 267.5K | 27.2K | 25.8K | |
| Begin Period Cash Flow | 2.4M | 23.9K | 34.4K | 221.2K | 413.0K | 490.4K | |
| Other Cashflows From Financing Activities | (256.4K) | 832.0K | 154.6K | 2.7M | 3.1M | 3.3M | |
| Other Non Cash Items | (285.1K) | (281.1K) | 560.6K | (1.6M) | (1.1M) | (1.0M) | |
| Total Cash From Operating Activities | (2.8M) | (765.2K) | (2.5M) | (1.4M) | (1.4M) | (1.5M) | |
| Net Income | (3.0M) | (1.6M) | (4.1M) | (743.2K) | (311.7K) | (327.3K) | |
| Total Cash From Financing Activities | 416.0K | 764.1K | 2.7M | 1.6M | 1.1M | 1.8M | |
| End Period Cash Flow | 23.9K | 34.4K | 221.2K | 413.0K | 59.2K | 56.2K | |
| Stock Based Compensation | 26.3K | 3.4K | 471.8K | 69.1K | 282.4K | 370.0K | |
| Change To Account Receivables | 33.0K | (11.7K) | 2.4K | (20.9K) | 44.2K | 46.4K | |
| Depreciation | 2.2K | 1.6K | 1.1K | 839.0 | 1.5K | 1.4K | |
| Change To Operating Activities | (222.5K) | 415.1K | 46.5K | (20.5K) | (23.6K) | (22.4K) | |
| Change To Netincome | 232.2K | (224.8K) | (102.5K) | 1.9M | 2.2M | 2.3M | |
| Change To Liabilities | 3.6M | 29.9K | 869.5K | (303.7K) | (349.3K) | (331.8K) | |
| Issuance Of Capital Stock | 416.0K | 656.8K | 1.1M | 1.6M | 2.2M | 1.6M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for RepliCel Stock Analysis
When running RepliCel Life's price analysis, check to measure RepliCel Life's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy RepliCel Life is operating at the current time. Most of RepliCel Life's value examination focuses on studying past and present price action to predict the probability of RepliCel Life's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move RepliCel Life's price. Additionally, you may evaluate how the addition of RepliCel Life to your portfolios can decrease your overall portfolio volatility.